Diagnostic strategies for pulmonary embolism in COVID-19.

Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-1965/coif). D.J.L.v.T. reports lecturing fees from Bayer and Boehringer-Ingelheim; he participated in Advisory Board meetings for Amarin, Sanofi, and Novartis; he is also the unpaid Board member of Dutch Society of Hypertension; and the authors’ institution received research fees/funding from Bayer, Ablative Solutions, and Idorsia; all unrelated to this manuscript. The other authors have no conflicts of interest to declare.